Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2904-2911

  Ahmed, Ashraf H ^a   Gordon, Richard D ^a   Sukor, Norlela ^a   Pimenta, Eduardo ^a   Stowasser, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; SPIRONOLACTONE;

ADRENALECTOMY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; EMOTIONAL STABILITY; FEMALE; FUNCTIONAL STATUS; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; MALE; MENTAL HEALTH; MONOTHERAPY; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT DURATION; VITAL SIGN;

ADRENALECTOMY; ADULT; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; AMILORIDE; AUSTRALIA; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RENIN; SOCIAL SUPPORT; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 80052525381     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0138     Document Type: Article

References (50)

1. Gordon R.D., Klemm S.A., Tunny T.J., Stowasser M. 1992 Primary aldosteronism: Hypertension with a genetic basis. Lancet 340:159-161
2. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., Sechi L.A. 2008 Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168:80-85
3. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., Sechi L.A. 2007 Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J AmSoc Nephrol 2:722-731
4. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248 (Pubitemid 40523144)
5. Rossi G.P., Bernini G., Desideri G., Fabris B., Ferri C., Giacchetti G., Letizia C., Maccario M., Mannelli M., Matterello M.J., Montemurro D., Palumbo G., Rizzoni D., Rossi E., Pessina A.C., Mantero F. 2006 Renal damage in primary aldosteronism: Results of the PAPY Study. Hypertension 48:232-238 (Pubitemid 44309817)
6. Clarke D., Wilkinson R., Johnston I.D., Hacking P.M., Haggith J.W. 1979 Severe hypertension in primary aldosteronism and good response to surgery. Lancet 1:482-485 (Pubitemid 9127245)
7. Lim P.O., Young W.F., MacDonald T.M. 2001 A review of the medical treatment of primary aldosteronism. J Hypertens 19:353-361 (Pubitemid 32195369)
8. Sechi L.A., Colussi G., Di Fabio A., Catena C. 2010 Cardiovascular and renal damage in primary aldosteronism: Outcomes after treatment. Am J Hypertens 23:1253-1260
9. Skevington S.M., Lotfy M., O'Connell K.A. 2004 The World Health Organization's WHOQOL-BREF quality of life assessment: Psy- chometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 13:299-310 (Pubitemid 38392258)
10. Muldoon M.F., Barger S.D., Flory J.D., Manuck S.B. 1998 What are quality of life measurements measuring? BMJ 316:542-545 (Pubitemid 28120965)
11. Testa M.A., Simonson D.C. 1996 Assessment of quality-of-life outcomes. N Engl J Med 334:835-840 (Pubitemid 26099607)
12. Canavarro M.C., Serra AV, Simo&tild;es MR, Rijo D, Pereira M, Gameiro S, Quartilho MJ, Quintais L, Carona C, Paredes T 2009 Development and psychometric properties of the World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) in Portugal. Int J Behav Med 16:116-124
13. Sukor N., Kogovsek C., Gordon R.D., Robson D., Stowasser M. 2010 Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 95:1360-1364
14. Avery T.L. 1984 Primary hyperaldosteronism and depression. N Z Med J 97:537
15. Khurshid K.A., Weaver M.E. 2005 Conn's syndrome presenting as depression. Am J Psychiatry 162:1226
16. Malinow K.C., Lion J.R. 1979 Hyperaldosteronism (Conn's disease) presenting as depression. J Clin Psychiatry 40:358-359 (Pubitemid 9232899)
17. Sonino N., Fallo F., Fava G.A. 2006 Psychological aspects of primary aldosteronism. Psychother Psychosom 75:327-330 (Pubitemid 44200481)
18. Hlavacova N., Jezova D. 2008 Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 54:90-97
19. Hlavacova N., Bakos J., Jezova D. 2010 Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 24: 779-786
20. Ware Jr J.E., Kosinski M., Gandek B. 2000 SF-36 Health survey: manual and interpretation. Lincoln, RI: QualityMetric Incorporated
21. Rocha R., Funder J.W. 2002 The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970:89-100 (Pubitemid 35286086)
22. Stowasser M., Taylor P.J., Pimenta E., Ahmed A.H., Gordon R.D. 2010 Laboratory investigation of primary aldosteronism. Clin Biochem Rev 31:39-56
23. McHorney C.A., Ware Jr J.E., Raczek A.E. 1993 The MOS 36-Item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263
24. McCallum J. 1995 The SF-36 in an Australian sample: Validating a new, generic health status measure. Aust J Public Health 19:160-166
25. Gonzaga C.C., Gaddam K.K., Ahmed M.I., Pimenta E., Thomas S.J., Harding S.M., Oparil S., Cofield S.S., Calhoun D.A. 2010 Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 6:363-368
26. Pimenta E., Calhoun D.A., Oparil S. 2009 Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis 51:371-380
27. Mulatero P., Stowasser M., Loh K.C., Fardella C.E., Gordon R.D., Mosso L., Gomez-Sanchez C.E., Veglio F., Young Jr W.F. 2004 Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045-1050 (Pubitemid 38368386)
28. Stowasser M., Gordon R.D., Gunasekera T.G., Cowley D.C., Ward G., Archibald C., Smithers B.M. 2003 High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non- selective'screening of hypertensive patients. J Hypertens 21:2149-2157 (Pubitemid 38296877)
29. Lichtenberg P., Belmaker R.H. 2010 Subtyping major depressive disorder. Psychother Psychosom 79:131-135
30. Murck H., Held K., Ziegenbein M., Künzel H., Koch K., Steiger A. 2003 The renin-angiotensin-aldosterone system in patients with depression compared to controls-a sleep endocrine study. BMC Psychiatry 3:15
31. Emanuele E., Geroldi D., Minoretti P., Coen E., Politi P. 2005 Increased plasma aldosterone in patients with clinical depression. Arch Med Res 36:544-548 (Pubitemid 41140063)
32. Wyrwich K.W., Harnam N., Revicki D.A., Locklear J.C., Svedsater H., Endicott J. 2011 Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form responder thresholds in generalized anxiety disorder and bipolar disorder studies. Int Clin Psychopharmacol 26:121-129
33. Gard P.R. 2004 Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 8:7-14 (Pubitemid 38240020)
34. Saavedra J.M., Ando H., Armando I., Baiardi G., Bregonzio C., Juorio A., MacovaM.2005 Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 128: 227-238 (Pubitemid 40544838)
35. Kaiser F.C., Palmer G.C., Wallace A.V., Carr R.D., Fraser-Rae L., Hallam C.1992 Antianxiety properties of the angiotensin II antagonist,DUP 753, in the rat using the elevated plus-maze. Neuroreport 3:922-924
36. Saavedra J.M., Armando I., Bregonzio C., Juorio A., Macova M., Pavel J., Sanchez-Lemus E. 2006 A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 31:1123-1134 (Pubitemid 43971830)
37. Srinivasan J., Suresh B., Ramanathan M. 2003 Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. Physiol Behav 78:585-591 (Pubitemid 36628085)
38. Naruse M., Tanabe A., Sato A., Takagi S., Tsuchiya K., Imaki T., Takano K. 2002 Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40:28-33 (Pubitemid 34755975)
39. Francis J., Beltz T., Johnson A.K., Felder R.B. 2003 Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-α in normal rats. Am J Physiol Regul Integr Comp Physiol 285:R1402-R1409 (Pubitemid 37464399)
40. Stier Jr C.T., Chander P.N., Rocha R. 2002 Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10:97-107 (Pubitemid 34246658)
41. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., Frei 3rd E., KufeD.W.1988 Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80:1039-1044
42. Capuron L., Miller A.H. 2004 Cytokines and psychopathology: Lessons from interferon-α. Biol Psychiatry 56:819-824
43. Raison C.L., Capuron L., Miller A.H. 2006 Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27:24-31 (Pubitemid 43083561)
44. Buchholz K., Schorr U., Turan S., Sharma A.M., Deter H.C. 1999 [Emotional irritability and anxiety in salt-sensitive persons at risk for essential hypertension]. Psychother Psychosom Med Psychol 49: 284-289
45. Deter H.C., Buchholz K., Schorr U., Schächinger H., Turan S., Sharma A.M. 1997 Psychophysiological reactivity of salt-sensitive normotensive subjects. J Hypertens 15:839-844 (Pubitemid 27344846)
46. Bitran D., Shiekh M., Dowd J.A., Dugan M.M., Renda P. 1998 Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol Biochem Behav 60:879-887 (Pubitemid 28349949)
47. Korte S.M., De Boer S.F., De Kloet E.R., Bohus B. 1995 Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze. Psychoneuroendocrinology 20:385-394
48. Smythe J.W., Murphy D., Timothy C., Costall B. 1997 Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacol Biochem Behav 56:507-513 (Pubitemid 27145833)
49. Funder J.W. 2004 Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217:263-269 (Pubitemid 38596652)
50. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl N.P. 2004 Low-renin status in therapy-resistant hypertension: A clue to efficient treatment. J Hypertens 22:2217-2226 (Pubitemid 39463817)